Meet us at PCR London Valves November 2025
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at PCR London Valves to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
Venus Medtech is committed to structural heart innovation. Our exceptional heart valve solutions target all four heart valves.
Be sure to join our symposium at PCR London Valves to better understand the mechanisms of action of the state-of-art Cardiovalve Replacement System for Tricuspid and Mitral Valve diseases and its current results.
Designed To Fit. Engineered To Last.
You are welcome to listen to top investigators who will discuss the latest results and future plans for the state-of-art Cardiovalve Replacement System for treating Tricuspid and Mitral Valve diseases.
Join our symposium: Tuesday 18 November 11:10 – 12:10 – Room Westminster
Cardiovalve Hits the TARGET:
Advancing Transcatheter Valve Replacement
Join leading expert as they present and discuss the latest results and future directions of the state-of-the-art Cardiovalve Replacement System for the treatment of Tricuspid and Mitral Valve diseases. Attend this session if you want to:
- Understand the anatomical and imaging challenges associated with transcatheter tricuspid valve replacement
- Gain insights into the latest advances in this rapidly developing clinical field.
- Be up-to-date on current developments in the Cardiovalve tricuspid clinical program.
Anchorperson: Azeem Latib.
Spokesperson: Georg Nickenig.
Panel Members: Scott Lim, Anna Sanino, Christian Frerker.
11:10
Session objectives
Azeem Latib
11:15
Cardiovalve TTVR: Step-by-Step Live-in-a-Box
Scott Lim
11:25
TARGET study: Interim Results
Georg Nickenig
11:40
TARGET Study Preliminary Echo Findings: More Than Just RV Reverse Remodeling
Anna Sannino
11:50
Simplifying TMVR: Early Human Experience with Next-Gen Cardiovalve Single-Step Approach
Christian Frerker
12:05
Session evaluation and key learnings
Azeem Latib
Learn more about TARGET
Multicenter Study
Learn more about the TARGET study below.
Multi-center Study
The TARGET Study
Evaluate the safety and performance of the Cardiovalve TR System with its associated procedure in reducing tricuspid regurgitation, signs of TR, and symptoms from TR.
150 participants
A total of 150 subjects will be enrolled. Up to a 5 year follow up.
Up to 50 Medical Center
Centers will be located in North America and Asia
Endpoints
Symptomatic subjects (NYHA Class ≥ II-IVa) with at least severe tricuspid regurgitation (≥3+ in a 5-tier grading) requiring valve replacement or repair who are at high risk for open chest surgery according to the Heart Team decision and approved by the Subject Screening Committee.
Innovation Never Stops!